- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Dr. Reddy's Laboratories Limited — Updates, 30-06-2026: General Updates
30-06-2026 | 07:42 pm
30-06-2026 | 07:42 pm
Dr. Reddy's reported FY26 revenue of ₹33,593 Cr (3% growth), driven by 16% India formulations growth. It launched generic Semaglutide in India/Canada and biosimilars in Europe/US. Regulatory inquiries in Ukraine closed. The company is committed to Net Zero by FY2045 with 78% renewable power.
No comments yet. Be the first to comment!